BHCM
IOVA icon

Brevan Howard Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Brevan Howard Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-525,519
Closed -$1.68M – 2293
2025
Q4 		$1.43M Buy
525,519
+253,552
+93% +$587K 0.02% 608
2025
Q3 		$590K Sell
271,967
-89,836
-25% -$212K ﹤0.01% 1193
2025
Q2 		$622K Buy
361,803
+254,188
+236% +$632K ﹤0.01% 1259
2025
Q1 		$358K Buy
107,615
+95,653
+800% +$493K ﹤0.01% 811
2024
Q4 		$88.5K Sell
11,962
-22,159
-65% -$205K ﹤0.01% 975
2024
Q3 		$320K Buy
34,121
+10,350
+44% +$98.1K ﹤0.01% 826
2024
Q2 		$191K Sell
23,771
-209,559
-90% -$2.25M ﹤0.01% 902
2024
Q1 		$3.46M Sell
233,330
-459,445
-66% -$5.35M 0.03% 99
2023
Q4 		$5.63M Sell
692,775
-869,911
-56% -$4.55M 0.07% 40
2023
Q3 		$7.11M Buy
1,562,686
+81,251
+5% +$530K 0.09% 32
2023
Q2 		$10.4M Buy
1,481,435
+947,265
+177% +$6.78M 0.22% 24
2023
Q1 		$3.26M Buy
534,170
+254,338
+91% +$1.75M 0.09% 61
2022
Q4 		$1.79M Hold
279,832
– – 0.06% 48
2022
Q3 		$2.68M Buy
279,832
+75,774
+37% +$874K 0.1% 34
2022
Q2 		$2.25M Buy
+204,058
New +$2.67M 0.09% 22

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Brevan Howard Capital Management's IOVA Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 525,519 shares — an estimated $1.68M sold.

Brevan Howard Capital Management first reported a position in IOVA in Q2 2022 and held it in 15 quarters. The position peaked at $10.4M in Q2 2023. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 525,519 Iovance Biotherapeutics shares in Q1 2026, an estimated $1.68M.
  • Brevan Howard Capital Management first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 15 quarters.
  • Brevan Howard Capital Management's Iovance Biotherapeutics position peaked at $10.4M in Q2 2023.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.